Stay updated with breaking news from Presentations Featured. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every...
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower
Biogen Inc.: Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients (nusinersen) Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and decisions for people with SMA CAMBRIDGE, Mass., April 19, 2021Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the d...
(diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life b...